文献速递脑血管病

无指南适应症的心源性栓塞性卒中急性期他汀治疗

Statin therapy in acute cardioembolic stroke with no guidance-based indication.
PubMed 文献 · Neurology · 2020-04-09

本研究基于前瞻性多中心卒中登记数据库,纳入2008至2015年住院的急性心源性栓塞性卒中患者,排除有其他他汀适应症者,采用稳定逆概率治疗加权脆弱模型分析。结果显示,在无指南适应症的心源性栓塞性卒中患者中,急性期启动他汀与主要血管事件、血管性死亡和全因死亡风险降低相关。

要点

  • 无指南适应症的心源性栓塞性卒中患者急性期他汀治疗与主要血管事件风险降低相关。
  • 他汀治疗与血管性死亡和全因死亡风险降低相关,但对卒中复发无显著影响。
  • 研究为观察性设计,结果需随机对照试验进一步验证。

核心结论

  • 在无指南适应症的心源性栓塞性卒中患者中,急性期启动他汀可能降低主要血管事件、血管性死亡和全因死亡风险。

研究设计与样本

  • 基于前瞻性多中心卒中登记数据库,纳入2008至2015年住院的急性心源性栓塞性卒中患者,排除有其他他汀适应症者,最终分析2888例。
  • 采用稳定逆概率治疗加权脆弱模型分析,估计他汀治疗对结局的风险比。

主要发现

  • 在2888例 eligible 患者中,1863例(64.5%)住院期间接受他汀治疗。
  • 中位随访359天,他汀组主要血管事件累积发生率为9.3%,非他汀组为20.5%(p < 0.001)。
  • 调整后风险比:主要血管事件0.39(95% CI 0.31-0.48),卒中复发0.81(95% CI 0.57-1.16),血管性死亡0.28(95% CI 0.21-0.36),全因死亡0.53(95% CI 0.45-0.61)。

临床怎么用

  • 对于无指南适应症的心源性栓塞性卒中患者,急性期启动他汀可能带来净获益,但需个体化评估。

局限性

  • 本研究为观察性研究,存在残余混杂可能,结果需随机对照试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: It is uncertain whether patients with cardioembolic stroke and without a guidance-based indication for statin therapy should be administered a statin for prevention of subsequent vascular events. This study was performed to determine whether the statin therapy is beneficial in preventing major vascular events in this population. METHODS: Using a prospective multicenter stroke registry database, we identified patients with acute cardioembolic stroke who were hospitalized between 2008 and 2015. Patients who had other established indications for statin therapy according to current guidelines were excluded. Major vascular event was defined as a composite of stroke recurrence, myocardial infarction, and vascular death. We performed frailty model analysis with the robust sandwich variance estimator using the stabilized inverse probability of treatment weighting method to estimate hazard ratios of statin therapy on outcomes. RESULTS: Of 6,124 patients with cardioembolic stroke, 2,888 (male 44.6%, mean age 75.3 years, 95% confidence interval [CI] 74.8-75.8) were eligible, and 1,863 (64.5%) were on statin therapy during hospitalization. After a median follow-up of 359 days, cumulative incidences of major vascular events were 9.3% in the statin users and 20.5% in the nonusers (p < 0.001 by log-rank test). The adjusted hazard ratios of statin therapy were 0.39 (95% CI 0.31-0.48) for major vascular events, 0.81 (95% CI 0.57-1.16) for stroke recurrence, 0.28 (95% CI 0.21-0.36) for vascular death, and 0.53 (95% CI 0.45-0.61) for all-cause death. CONCLUSION: Starting statin during the acute stage of ischemic stroke may reduce the risk of major vascular events, vascular death, and all-cause death in patients with cardioembolic stroke with no guidance-based indication for statin.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Park HK, Lee JS, Hong KS, et al. Statin therapy in acute cardioembolic stroke with no guidance-based indication. Neurology. 2020. PMID: 32273430. doi:10.1212/WNL.0000000000009397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。